Analysis Flags Ethics Concerns in 853 IHU Papers, Including 758 Co-Authored by Didier Raoult
Updated
Updated · The Guardian · Aug 19
Analysis Flags Ethics Concerns in 853 IHU Papers, Including 758 Co-Authored by Didier Raoult
1 articles · Updated · The Guardian · Aug 19
Summary
An international research team found “substantial” ethical or legal concerns in 853 papers from Marseille’s IHU Méditerranée Infection, far more than earlier probes had identified.
Raoult was a co-author on 758 of those papers; the review said at least 78 studies appeared noncompliant with French law, 343 recorded no ethics approval, and some approvals were obtained retrospectively or reused.
The findings have already fed into 64 retractions and 270 expressions of concern, and the authors urged broader review of the institute’s record and of Aix-Marseille University’s oversight.
Raoult’s influence extended beyond France because his hydroxychloroquine paper—retracted in 2025—was promoted in 2020 by Donald Trump, Mehmet Oz and Robert F. Kennedy Jr despite early scientific criticism.
Aix-Marseille University said it acted responsibly after being alerted in 2020 and strengthened oversight, while Raoult, who retired in 2021, did not answer the new allegations directly.
How did hundreds of ethically flawed medical studies slip past global peer-review systems for nearly three decades unnoticed?
Could the systemic failure to verify ethics approvals mean other accepted medical treatments are built on illegal foundations?
What hidden institutional pressures drove a top research center to bypass basic human-subject safety laws for years?
46 Retractions, 218 Expressions of Concern: Inside the Didier Raoult and IHU-Marseille Research Integrity Crisis
Overview
The report reveals how Didier Raoult’s unauthorized clinical trials and flawed COVID-19 research at IHU-Marseille led to escalating legal, professional, and scientific consequences. A French court banned Raoult from practicing medicine, while investigations exposed systemic ethical violations, including the repeated misuse of a single ethics approval across hundreds of studies and experiments on vulnerable populations. Publishers launched massive audits, resulting in dozens of retractions and expressions of concern. Raoult’s widely publicized, but deeply flawed, hydroxychloroquine study fueled global misinformation, political endorsement, and patient harm. These scandals have driven major reforms in research oversight, clinical trial regulation, and publication standards across Europe and the UK.